

July 28, 2026

To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
NSE Symbol: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 34/26-27	Our Reference No. 34/26-27

Dear Sir/ Madam,

Sub: Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION[®]2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].

According to IQVIA[®] sales data for the 12-month period ending May 2026, the BRIDION[®] Injection, 100 mg/mL market³ achieved annual sales of approximately \$1.6 billion*.

Kindly find attached media release which is self- explanatory.

Request you to kindly take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS - 28839

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

**Glenmark Pharmaceuticals Inc., USA launches
Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and
500 mg/5 mL (100 mg/mL) Single-Dose Vials**

Elmwood Park, New Jersey, July 28, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^{®2} Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].

According to IQVIA[®] sales data for the 12-month period ending May 2026, the BRIDION[®] Injection, 100 mg/mL market³ achieved annual sales of approximately \$1.6 billion*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The launch of Sugammadex Injection represents a significant addition to Glenmark's growing U.S. injectables portfolio and strengthens our presence in the hospital and institutional segment. Achieving a Day 1 launch reflects the agility, preparedness and execution discipline behind our injectable strategy. It also underscores our ability to identify meaningful market opportunities, support greater supply reliability and expand access to high-quality and affordable medicines across the U.S healthcare system.”

¹Glenmark's Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials is only approved for the indication(s) listed in Glenmark's approved label.

²All brand names and trademarks are the property of their respective owners.

³Market includes brand and all available therapeutic equivalents. Note: IQVIA[®] data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for and will only be marketed for the indications listed in Glenmark's approved label, which may be different than the approved RLD indications.

*IQVIA[®] National Sales Perspectives: Retail & Non-Retail, May 2026

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact:

India	United States
Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999 Adfactors PR glenmark.ihcp@adfactorspr.com	Akhila Natarajan mediarelations@glenmarkpharma.com Danielle Hagen danielle@nahigianstrategies.com 202-365-6112